Flotek Industries heads into its May 6 Q1 print with shorts adding positions, options traders positioned bullishly, and a dominant strategic shareholder sitting on more than half the float — a setup full of competing pressures.
Short interest has climbed 6.2% over the past week to 7.7% of the free float, reversing a month-long decline that had taken it down roughly 7% from March highs. The rebuild is modest in share terms — roughly 188,000 additional shares added since April 23 — but the direction of travel has shifted ahead of the earnings date. ORTEX's short score is a high 76.8, well above neutral, reflecting both the level of short interest and the positioning dynamics in the lending market. Borrow costs, by contrast, have eased sharply: the cost to borrow has fallen roughly 43% over the past month to just 0.55% annualised, near the low end of its recent range. Availability is around 90%, meaning the lending pool is not tight, and new shorts face no material friction in establishing positions. Days to cover is elevated at over 14 — one of the highest readings in the sector — suggesting any sustained buying pressure would take time to unwind existing short positions.
Options traders are reading the setup differently. The put/call ratio has dropped to 0.22 this week, well below its 20-day average of 0.28 and roughly one standard deviation below that mean. Call-side demand has dominated for several sessions running, a sharp rotation from late April when the ratio briefly spiked above 0.39-0.40. The current PCR is near the lower end of its 52-week range (0.08 low, 0.52 high), suggesting this week's options flow is among the most bullishly skewed of the year. The stock has recovered 1.1% on the week to $16.94, clawing back most of a 2.8% one-month slide. RSI sits at a neutral 55, providing no overbought or oversold read ahead of the print.
The Street is moderately constructive, though the analyst base is thin and the most recent coverage actions are now months old. The consensus mean price target of $21.25 implies roughly 25% upside from current levels — Northland Capital Markets reiterates an Outperform with a $20 target, while Roth MKM carries a Buy with an $8 target (the latter figure appears inconsistent with the current $17 price and should be treated with caution, likely reflecting a dated or pre-rerating target). The PE multiple of 21.1x and EV/EBITDA of 11.2x have both edged lower over the past month, while the price-to-sales ratio of 0.80x remains modest for a specialty chemicals name. Factor scores are mixed: short score ranks in the top percentile of the universe (a bearish signal) while earnings surprise history ranks at the 33rd percentile, suggesting the company has not been a consistent beat story.
The ownership structure is the sharpest feature of this stock. ProFrac Holding Corp. controls 58% of shares outstanding, having added 6 million shares as recently as March 13. That concentration compresses the effective float considerably and shapes how any short position plays out. The next-largest institutional holders — Driehaus Capital Management, which built an 830,000-share position nearly from scratch at year-end, and Vanguard adding 51,500 shares through March — are acting on the long side. Insider activity from the most recent 90-day window was net positive in share terms (roughly 31,000 net shares), though this reflects stock awards outweighing the modest $100,000-$195,000 in open-market sells by the CEO and CFO in late February at around $16 — near the current price.
The last two earnings prints produced a positive 1-day move of 2.3-4.9% before fading to flat or slightly negative by the end of the week. With Q1 results due May 6, the tension between a short score near multi-month highs, the optically bullish options flow, and a tightly-held float compressed by a majority shareholder makes the shape of the post-earnings reaction — and the pace of any short covering — the key variable to track.
See the live data behind this article on ORTEX.
Open FTK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
